Twenty-one patients with advanced stage, non-small-cell lung carcinoma were treated with a chemotherapy regimen including: mitomycin (6 mg/m2), ifosfamide (3 g/m2), cisplatin (80 mg/m2). The regimen was administered on an outpatient basis. Two patients were lost to follow-up. Among the 29 patients evaluable for response we registered a response rate of 36.8 %; 36.8% of patients had stable disease, and 15.7 % progressed during treatment. Median duration was 8.7 months and median survival was 11 months. Toxicity was low and easily manageable on an outpatient basis.
Get full access to this article
View all access options for this article.
References
1.
ArdizzoniA., CanobbioC., PronzatoP.: Etoposide and high dose cisplatin in good-risk patients with advanced squamous cell carcinoma and adenocarcinoma of the lung. Cancer Treat. Rep., 70: 891–892, 1986.
2.
ArdizzoniA., FuscoV., GulisanoM.: VP 16, ifosfamide, cisplatin (VIP) in the treatment of advanced non-small cell lung cancer. Cancer Treat. Rep., 71: 1311–1312, 1987.
3.
CullenM., JoshiR., ChetiyawardanaA., WoodroffeC.: Mitomycin, ifosfamide and cisplatin in non small cell lung cancer: treatment good enough to compare. Br. J. Cancer58: 359–361, 1988.
4.
CurieD., MilesD., DrakeJ., RuddR.: Mitomycin, ifosfamide and cisplatin in non small cell lung cancer. Cancer Chemother. Pharmacol., 25: 380–381, 1990.
5.
GironC., OrdonezA., JalonJ., BaronM.: Combination chemotherapy with ifosfamide, mitomycin, and cisplatin in advanced non small cell lung cancer. Cancer Treat. Rep., 71: 851–853, 1987.
KrisM., CohenE., GrallaR.: An analysis of 134 phase II trials in non small cell lung cancer. Proc. 4th World Conf. on Lung Cancer, Toronto, Canada, 4, 39 abs, 1985.
8.
KrisM., GrallaR., TysonL.: Antiemetic control of cisplatin-induced emesis with high-dose metoclopramide and with combinations of metoclopramide, dexamethasone, and diphenhydramine: Results of consecutive trials in 255 patients. Cancer, 55: 527–534, 1985.
9.
RankinE.: Non small cell lung cancer. In: Randomized Trials in Cancer: A Critical Review.Sites-SlevinM., StaquetM. (Eds.), Raven Press, New York, 1986.
10.
RossoR., SalvatiF., ArdizzoniA.for the FONICAP: Etoposide versus etoposide plus high-dose cisplatin in the management of advanced non-small cell lung cancer: results of a prospective randomized trial. Cancer, 66: 130–134, 1990.
11.
World Health Organisation:Handbook for reporting results of cancer treatment.WHO Offset Publ, 48 Geneva; 1979. Cancer Treat. Rep., 71: 1311–1312, 1987.
